1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53:1801913. PMID:
30545968.
Article
2. Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016; 133:1240–1248. PMID:
26873944.
Article
3. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022; 327:1379–1391. PMID:
35412560.
Article
4. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015; 373:834–844. PMID:
26308684.
Article
5. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115:343–349. PMID:
1863023.
6. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012; 142:448–456. PMID:
22281797.
Article
7. Jang AY, Lee H, Kim HC, Chung JW. Epidemiology of targeted therapy-treated PAH in Korea: an analysis of the national health insurance data, 2002-2018. Korean Circ J. 2023; 53:313–327. PMID:
37161745.
Article
8. Lim SS, Lee W, Kim YK, et al. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011-2015. Orphanet J Rare Dis. 2019; 14:49. PMID:
30777110.
Article
9. Lee JH, Hwang KK. End-of-life care for end-stage heart failure patients. Korean Circ J. 2022; 52:659–679. PMID:
36097835.
Article
10. Oh S, Jung JH, Ahn KJ, et al. Stem cell and exosome therapy in pulmonary hypertension. Korean Circ J. 2022; 52:110–122. PMID:
35128849.
Article